Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 266Lung Neoplasms 102Adenocarcinoma of Lung 28Mesothelioma, Malignant 24Mesothelioma 22Neoplasms 18Meningeal Carcinomatosis 18Brain Neoplasms 16Head and Neck Neoplasms 14Neoplasm Metastasis 13Ovarian Neoplasms 9NSCLC 9Colorectal Neoplasms 8Adenocarcinoma, Bronchiolo-Alveolar 8Breast Neoplasms 7Recurrence 6Carcinoma, Transitional Cell 6Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Lymphoma 5Esophageal Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 4Sarcoma 4Non-squamous Non-small Cell Lung Cancer 4Non-small Cell Lung Cancer Metastatic 4Fallopian Tube Neoplasms 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Stomach Neoplasms 3

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × Pemetrexed × Clear all
NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02624700 2020-07-14

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

Virginia Commonwealth University

Phase 2 Terminated
13 enrolled 13 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡